Cancer treatment of the future


Do we hear the patient's voice?

onsdag 27. mars 2019, kl. 08:15 til kl. 10:00

Sal: Wergeland

Arrangør: Oslo cancer cluster

Inngang: Gratis med påmelding

This page is not available in English. Below is the Norwegian page translated by Google.

Welcome to breakfast in the meeting series Future Cancer Treatment. This morning we will go into more detail about the patient's opportunities to participate in decision-making processes regarding new cancer treatment.

Are the patients at the center of decision making? We will talk to patient organizations, user representatives and authorities during this breakfast meeting in the meeting series “Future Cancer Treatment”.

08:00 - 08:30: Breakfast is served.
08.30–08.50: Secretary of State Anne Grethe Erlandsen from the Ministry of Health and Care Services opens.
08.50–09.15: Ellen Nilsen , special adviser to the Secretariat New Methods, presents the system in New Methods and the background for it.
09.00–10.15: Conversation between representatives from user committees, patient associations, Norwegian Medicines Agency, Order Forum and cancer doctors.

Participants in the conversation are Tove Nakken , chair of the user committee at Oslo University Hospital and the Lymphoma Cancer Society, Heidi Brorson , member of the user committee in the Health Southeast and special adviser in the Cancer Society, a representative from the Norwegian Medicines Agency, Jan Frich , director of medicine and health science, Health Sør. RHF and department director in the Order Forum and Odd Terje Brustugun , chief physician at Drammen Hospital. The moderator of the conversation is Markus Moe , editor of Today's Medicine.

The conversation will try to answer questions such as: How is the patient participation system today? Is that good enough? What can patients contribute that can be important when considering new cancer treatments?

Finally, we open up questions from the hall.

The meeting is free and open to all. Sign up here.

The meeting is a collaboration between the Oslo Cancer Cluster, the Pharmaceutical Industry (LMI), Janssen Norway, AstraZeneca Norway and MSD Norway.